MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

14.03.2023 - -   Announced positive clinical data from AQUAx AAV-hAQP1 Phase 1 trial for treatment of Grade 2/3 Radiation-Induced Xerostomia in December 2022 -   Announced positive top-line data from the MGT009 Phase 1/2 clinical study demonstrating safety and ...

Related Keywords

United States ,Ireland ,United Kingdom ,London ,City Of ,American ,Jason Braco ,Botaretigene Sparoparvovec ,American Academy Of Ophthalmology Annual Meeting ,Lifesci Communications ,Meiragtx Holdings ,European Society Of Gene ,Janssen Pharmaceuticals Inc ,Janssen Pharmaceutical Companies Of Johnson ,Nasdaq ,Alexandria Forbes ,European Society ,Cell Therapy ,Annual Congress ,Lumeos Phase ,Development Highlights ,Retina Subspecialty Day ,Janssen Pharmaceuticals ,Janssen Pharmaceutical Companies ,Induced Xerostomia ,Patient Reported Outcome ,Global Rate ,Xerostomia Questionnaire ,Gene Regulation Platform ,Vector Engineering ,Therapy Manufacturing ,Quality Control ,Private Securities Litigation Reform Act ,Annual Report ,Gene Therapy Trial ,X Linked Retinitis Pigmentosa ,Ophthalmology Annual ,Years Ended December ,